{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:48:15Z","timestamp":1761896895041,"version":"build-2065373602"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T00:00:00Z","timestamp":1654646400000},"content-version":"vor","delay-in-days":1285,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","exphem.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Hematology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.exphem.2018.09.007","type":"journal-article","created":{"date-parts":[[2018,10,4]],"date-time":"2018-10-04T12:37:25Z","timestamp":1538656645000},"page":"62-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation"],"prefix":"10.1016","volume":"68","author":[{"given":"Laura M.","family":"Haunstrup","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lene H.","family":"Ebbesen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne T.","family":"Severinsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anni","family":"Aggerholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exphem.2018.09.007_bib0001","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.09.007_bib0002","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.3109\/10428194.2015.1116122","article-title":"JAK2V617F and CALR double mutations are more frequently encountered in patients with low JAK2V617F allelic burdens","volume":"57","author":"Mansier","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2018.09.007_bib0003","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jmoldx.2016.08.006","article-title":"Detection of CALR and MPL mutations in low allelic burden JAK2 V617F essential thrombocythemia","volume":"19","author":"Usseglio","year":"2017","journal-title":"J Mol Diagn"},{"key":"10.1016\/j.exphem.2018.09.007_bib0004","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.3109\/10428194.2015.1091932","article-title":"Increased frequency of coexisting JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden","volume":"57","author":"Nussenzveig","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.exphem.2018.09.007_bib0005","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.09.007_bib0006","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.exphem.2018.09.007_bib0007","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2141.2007.06497.x","article-title":"The JAK2 V617F mutation involves B- and T-lymphocyte lineages in a subgroup of patients with Philadelphia-chromosome negative chronic myeloproliferative disorders","volume":"136","author":"Larsen","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.exphem.2018.09.007_bib0008","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.exphem.2018.09.007_bib0009","doi-asserted-by":"crossref","first-page":"E84","DOI":"10.1002\/ajh.25014","article-title":"Clinical and biological characterization of MPN patients harboring two driver mutations, a French intergroup of myeloproliferative neoplasms (FIM) study","volume":"93","author":"Mansier","year":"2018","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.09.007_bib0010","doi-asserted-by":"crossref","first-page":"57036","DOI":"10.18632\/oncotarget.10958","article-title":"Coexistence of JAK2 and CALR mutations and their clinical implications in patients with essential thrombocythemia","volume":"7","author":"Kang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.exphem.2018.09.007_bib0011","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.exphem.2018.09.007_bib0012","doi-asserted-by":"crossref","first-page":"E121","DOI":"10.1002\/ajh.23743","article-title":"Type 1 versus Type 2 calreticulin mutations in essential thrombocythemia: a collaborative study of 1027 patients","volume":"89","author":"Tefferi","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.exphem.2018.09.007_bib0013","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1038\/leu.2014.83","article-title":"Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact","volume":"28","author":"Tefferi","year":"2014","journal-title":"Leukemia"}],"container-title":["Experimental Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18308488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0301472X18308488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T08:33:30Z","timestamp":1759566810000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0301472X18308488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":13,"alternative-id":["S0301472X18308488"],"URL":"https:\/\/doi.org\/10.1016\/j.exphem.2018.09.007","relation":{},"ISSN":["0301-472X"],"issn-type":[{"type":"print","value":"0301-472X"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Skewed ratio between type 1 and type 2 calreticulin mutations in essential thrombocytosis patients with concomitant Janus kinase 2 V617F mutation","name":"articletitle","label":"Article Title"},{"value":"Experimental Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exphem.2018.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 ISEH -- Society for Hematology and Stem Cells. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}